The EMEA unveiled several changes to the organization, including a new structure and visual identity.
The EMEA has unveiled several changes to the organization, including a new structure and visual identity.
One primary structural change involves integrating human pre- and post-authorization activities into one unit, “to guarantee seamless lifecycle-management of medicines,” according to a press statement. Also, a group will be dedicated to the management of product data and documentation to help improve the efficiency of data-management processes throughout the agency.
This is the second time the EMEA has undergone restructuring. Established in 1995, the agency’s “responsibilities and tasks have grown, giving it a stronger role in the protection of public and animal health in Europe,” according to the press statement. “All of this has been underpinned by the creation of additional scientific committees and advisory groups, which bring with them the need for enhanced coordination and support. Legislative proposals currently being considered by the European Parliament and Council are expected to bring further responsibilities to the Agency.”
As part of the agency’s new visual, or public, identity, the EMEA will launch a new website in the coming months. The site is expected to be easier for the public to use and designed to meet readers’ needs.
Going forth, the agency will now be known as the EMA as opposed to the EMEA.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.